levelcanbeaffectedinsomepatients.Aggressiveearly treatmentisassociated with better recovery. In with anti-phospholipid antibodies (which this patient did not have), anticoagulation combined with glucocorticoids and immunosuppressive treatment may achieve animproved outcome. Key Learning Points: Transverse myelitis is a rare complication of systemic lupus erythematosus. Transverse myelitis can occur even when other parameters of SLE are quiescent. On neuroimaging alone, it can be difficult to distinguish causes of spinal cord inflammation and treatment decisions may need to be made on the basis of most likely diagnosis from imaging, history and risk factors and monitoredover time. She was treated by neurology for a clinically isolated syndrome with oral methylprednisolone 500 mg for five days. Her diplopia completely resolved after two weeks. She is currently awaiting to have alumbar puncture and MRI brain scan with gadolinium. Alternative treatments are being consideredfor her AS. Discussion: There was high clinical suspicion of demyelination given the use of anti-TNF treatment and new, persistent neurological symptoms. The CT head was done prior to clinic review and did not show an alternative cause e.g. space-occupying lesion. It was therefore felt necessary to suspend treatment until the more sensitive MRI scan was performed with neurology input. Once the likelihood of demyelination was confirmed, anti-TNF was stopped indefinitely and further treatment would be reviewed later given the AS was clinically quiescent. Initial animal studies demonstrated beneficial effects of anti-TNF therapy in multiple sclerosis (MS) and subsequent human trials used infliximab and lenercept in patients with MS. However, the results were staggering as both treatments caused worsening of disease. Moreover, there have been an increasing number of demyelinating events with the growing use of anti-TNF. Kemanetzoglou et al. found 122 published cases of CNS demyelinating events in patients treated with anti-TNF between January 1990 and August 2016. The mean time from exposure of anti-TNF to onset of neurological symptoms was 17.6 months. The mean age of onset was 45 years; later than typical presentations of MS but similarly there was a female preponderance -61% of all reported cases. Interestingly, only three patients had a reported family history of MS. 50% of patients had RA with only 11% having AS. 16% had PsA, 8% had Crohn's disease and the remainder had other inflammatory conditions. The majority (47%) were treated with etanercept, followed by infliximab in 41% of cases. 16% were treated with adalimumab and 1% had golimumab. Three patients received more than one anti-TNF drug. Recovery after initial therapy was complete in 36% of patients but only partial in 21%. There was no resolution in symptoms in 28% of patients and three patients died -two with PML and one with MDE.
Rheumatology, East Midlands, Lincoln, UNITED KINGDOM Introduction: Anti-tumour necrosis factor (TNF) alpha treatment is commonly used in rheumatology, gastroenterology and other specialties to control conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), rheumatoid arthritis (RA) and Crohn's disease. Examples include etanercept, adalimumab, infliximab, golimumab and certolizumab. Their effectiveness is often superior to conventionally used disease-modifying anti-rheumatic drugs (DMARDs) and the side-effect profile thought to be relatively safe. However, clinical trials using anti-TNF to treat multiple sclerosis worryingly demonstrated increased disease activity rather than clinical improvement. Although etanercept was not used in these trials, there have been rare reports of it causing both central nervous system (CNS) and peripheral nervous system demyelination. This case once again highlights this concerningcomplication of anti-TNF therapy. Case description: A 58 year old woman presented to the rapid access eye clinic with sudden onset diplopia whilst driving. She did not experience any headaches, vomiting or additional focal neurological symptoms. Her past medical history included a delayed diagnosis of AS in 2016 on a background of longstanding back pain, which was well controlled with subcutaneous etanercept 50 mg weekly. She had been treated with etanercept for over a year, with one short break in treatment due to transient leucopenia. Clinical examination revealed aleft 6th cranial nerve palsy with visual acuity 6/6 bilaterally, normal pupillary response, fundus examination and intraocular pressures. There was no other neurological deficit in cranial nerve or peripheral neurological examinations. Urgent CT head was unremarkable but her symptoms persisted. Her etanercept was stopped in the rheumatology clinic with urgent MRI brain and neurology review arranged. The MRI scan demonstrated an area of high signal intensity in the dorsal left pons, with additional small foci adjacent to the posterior horn of the left lateral ventricle; consistent with demyelination. She was treated by neurology for a clinically isolated syndrome with oral methylprednisolone 500 mg for five days. Her diplopia completely resolved after two weeks. She is currently awaiting to have alumbar puncture and MRI brain scan with gadolinium. Alternative treatments are being consideredfor her AS. Discussion: There was high clinical suspicion of demyelination given the use of anti-TNF treatment and new, persistent neurological symptoms. The CT head was done prior to clinic review and did not show an alternative cause e.g. space-occupying lesion. It was therefore felt necessary to suspend treatment until the more sensitive MRI scan was performed with neurology input. Once the likelihood of demyelination was confirmed, anti-TNF was stopped indefinitely and further treatment would be reviewed later given the AS was clinically quiescent. Initial animal studies demonstrated beneficial effects of anti-TNF therapy in multiple sclerosis (MS) and subsequent human trials used infliximab and lenercept in patients with MS. However, the results were staggering as both treatments caused worsening of disease. Moreover, there have been an increasing number of demyelinating events with the growing use of anti-TNF. Kemanetzoglou et al. found 122 published cases of CNS demyelinating events in patients treated with anti-TNF between January 1990 and August 2016. The mean time from exposure of anti-TNF to onset of neurological symptoms was 17.6 months. The mean age of onset was 45 years; later than typical presentations of MS but similarly there was a female preponderance -61% of all reported cases. Interestingly, only three patients had a reported family history of MS. 50% of patients had RA with only 11% having AS. 16% had PsA, 8% had Crohn's disease and the remainder had other inflammatory conditions. The majority (47%) were treated with etanercept, followed by infliximab in 41% of cases. 16% were treated with adalimumab and 1% had golimumab. Three patients received more than one anti-TNF drug. Recovery after initial therapy was complete in 36% of patients but only partial in 21%. There was no resolution in symptoms in 28% of patients and three patients died -two with PML and one with MDE.
Key Learning Points: Although rare, there should be a high index of suspicion of demyelination in all patients treated with anti-TNF therapy (including biosimilars) who develop persistent neurological symptoms. Isolated 6th cranial nerve palsy is often a false localising sign but in this case was caused by demyelination in the pons; where the cranial nerve nucleus was located. Family history of MS does not appear to be associated with significant increased risk of demyelination with anti-TNF treatment. Just over a third of patients obtain full recovery after initial therapy. Data forlonger follow up periods appears tobe lacking. Disclosure: M. Chakravorty: None. S. Obaid: None. Introduction: This case report describes a 67 year old female patient with SLE who was diagnosed with inclusion body myositis after extensive investigation for symptoms of progressive muscle weakness after initial treatment for presumed SLE-associated myositis. Case description:Initially the patient presented with symptoms of flitting arthralgia, myalgia, mouth ulcers and sicca symptoms. Blood results showed intermittent leucopenia, positive ANA (titre 1: 1600), raised dsDNA 59.1 and low C4 levels 0.12. ENA was negative and creatine kinase levels within normal range. Background of aduodenal GIST (gastrointenstinal stromal tumour) with liver metastases with surgical resection in 2012 and ongoing treatment with tyrosine kinase inhibitor (masitinib) as part of a clinical trial. Treatment with hydroxychloroquine 200 mg bd and a reducing course of oral prednisolone was commenced. Initial response to treatment was favourable with no features of active SLE on subsequent clinic reviews. November 2016 saw worsening muscle weakness with difficulty to from sit to stand and climbing stairs. Evidence of proximal weakness, most severe in hip flexors (power 4/5), particularly in the left leg with preservation of distal power. Blood tests showed a mildly elevated creatine kinase 256, however normal inflammatory markers. MRI imaging of thighs showed subtle asymmetrical signal in the adductor longus muscles and left biceps femoris muscle. MRI Spine showed no cord compression nor metastatic spinal involvement. CT imaging showed no progression of malignancy. EMG showed low amplitude short duration units in keeping with a myopathy but no evidence of myositis. The muscle biopsies from the right medial thigh and left posterior thigh showed patchy vacuolated fibres throughout the muscle fascicles but no inflammation. Lamellated inclusions were observed within many myofibres in association with autophagic vacuoles containing degenerate material. Hydroxychloroquine was stopped due to the possibility of a drug induced vacuolar myopathy. The patient was referred for aneuromuscularopinion at the nearest tertiary centre. The muscle weakness persisted despite withdrawal of hydroxychloroquine. SLE treatment was challenging once hydroxychloroquine was stopped. Masitinib treatment posed a risk of neutropenia, therefore treatment with mycophenolate or azathioprine was difficult. A further complication was a prolonged hospital admission with a Klebsiella cavitating pneumonia in 2017. During this admission patient developed profound thrombocytopaenia (platelets 15) and also had low IgG 4.50. Initially prednisolone was increased to 1 mg/kg. She was later treated with iv immunoglobulins 2g/kg in October 2017 on the basis of presumed SLE-mediated myositis in addition to ongoing thrombocytopaenia and hypogammaglobinaemia. This did result in a documented improvement to graded muscle power, particularly in the legs, but effects were transient. Further course of immunoglobulin 2g/kg due to persistent and recurrent infection was given in March 2018 with similar effect. At neuromuscular specialist review in April 2018 there was further deterioration in mobility and also swallowing difficulties. There was predominant weakness in left wrist flexion and finger flexion and extension Facial muscle and neck flexor weakness were also noted as well a loss of knee jerks. A diagnosis of inclusion body myositis was made based on clinical findings and review of previous investigations. Investigation findings has not been fully conclusive, however the pattern of asymmetrical muscle group involvement, particularly affecting finger flexors associated with loss of knee jerks, swallowing problems and modest creatine kinase elevation were in keeping with this diagnosis. There had also been failure to respond to steroid treatment and evidence of vacuolated muscle fibres from the biopsy. Ongoing management involved referral to the specialist neuromuscular physiotherapist and input from speech and language therapist to address swallowing difficulty. Discussion: Inclusion body myositis is a slowly progressive inflammatory myopathy which is characterised by asymmetrical distal and proximal weakness, particularly affecting the finger and wrist flexors and quadriceps. Inclusion body myositis has been associated with immune mediated conditions, however is usually resistant to treatment with conventional immunotherapies. There have been previous case reports of inclusion body myositis associated with SLE which show similarities to
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